Halegoua-de Marzio Research

A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Compensated Cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Sponsor: 89Bio, Inc.

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of EFRUXIFERMIN in NON-CIRRHOTIC Subjects with Nonalcoholic Steatohepatitis (NASH) and Fibrosis

Sponsor: Akero Therapeutics, Inc.

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Sponsor: Akero Therapeutics, Inc.

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Non- Invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Sponsor: Akero Therapeutics, Inc.

Global Longitudinal Assessment of Nonalcoholic Fatty Liver Disease (NAFLD) using Magnetic Resonance Elastography GOLD-MINE study.

Sponsor: AstraZeneca Pharmaceuticals and UCSD

A Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Effect of Resmetirom on Liver-related Outcomes in Patients with Well-compensated (Child-Pugh A) Non-alcoholic Steatohepatitis (NASH) Cirrhosis (MAESTRO-NASH OUTCOMES)

Sponsor: Madrigal Pharmaceuticals

A Multi-Center, Longitudinal Study of Drug- and HDS-Induced Liver Injury

Sponsor: NIH